Correspondence 0001193125-23-146990 from Clearside Biomedical, Inc. (CLSD) (CIK 0001539029) (CLSDQ)
Clearside Biomedical, Inc. (CLSD) (CIK 0001539029)
Date: May 17, 2023 · CIK: 0001539029 · Accession: 0001193125-23-146990
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271902
Letter
May 17, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: Lauren S. Hamill
Re: Clearside Biomedical, Inc.
Registration Statement on Form S-3
File No. 333-271902
Acceleration Request
Requested Date: May 19, 2023
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271902) (the “Registration Statement”) to become effective on May 19, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff.
Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Asheley Walker at (202) 842-7856.
[Signature page follows]
Very truly yours,
Clearside Biomedical, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
May 17, 2023
Via EDGAR
U.S. Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn:
Lauren S. Hamill
Re:
Clearside Biomedical, Inc.
Registration Statement on Form S-3
File No. 333-271902
Acceleration Request
Requested Date: May 19, 2023
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the
Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271902) (the “Registration Statement”) to become effective on May 19, 2023, at 4:00 p.m. Eastern Time, or as
soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff.
Once the Registration
Statement has been declared effective, please orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Asheley Walker at (202) 842-7856.
[Signature page follows]
Very truly yours,
Clearside Biomedical, Inc.
By:
/s/ Charles A. Deignan
Charles A. Deignan
Chief Financial Officer
cc:
George Lasezkay, Clearside Biomedical, Inc.
Mark Ballantyne, Cooley LLP
Asheley Walker, Cooley LLP